Роль блокаторов рецепторов ангиотензина в лечении артериальной гипертонии: фокус на лозартан

1. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
2. Диагностика и лечение артериальной гипертензии. Национальные клинические рекомендации. ВНОК. М., 2008.
3. Veronesi M, Cicero AF, Prandin MG. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice Vasc Health Risk Manag 2007; 3 (6): 999–1005.
4 Veronesi M., Cicero A.F., Prandin M.G. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice Vasc Health Risk Manag. 2007;3 (6):999-1005.
5. Blood Pressure Lowering Treatment Trialists' Collaboration  Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system J Hypertens 2007; 25 (7): 1524.
6. Dahlof B, Devereux R, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995–1003.
7. Nichols W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18 (1 Pt 2): 3S–10S.
8. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.
9. Lindholm LH, Ibsen H, Borch-Johnsen K. For the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20 (9): 1879–86.
10. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23 (4): 891–8.
11. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet. 2003; 362 (9384): 619–20.
12. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet 2003; 362 (9384): 591–2.
13. Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2. diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9.
14. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 6 (355): 1582–7.
15. Shahinfar S, Lyle PA, Zhang Z et al. Losartan: lessons learned from the RENAAL study. Expert Opin Pharmacother 2006; 7 (5): 623–30.
16. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журн. сердечн. недостат. 2007; 8: 2.
17. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial.Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
18. Kamper A, Nielsen A. Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001; 72 (4): 671–4.
19. Hamada T, Ichida K, Hosoyamada M. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients Am J Hypertens 2008; 21 (10): 1157–62.
20. Many A, Hubel C, Roberts J. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 1996;174 (1 Pt 1):288–291.
21. Кобалава Ж.Д., Толкачева В.В. Мочевая кислота – ключевое связующее звено кардиоренального континуума? Часть I. Клин. фармакол. и тер. 2003; 12: 15–9.
22. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787–90.
23. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14 (17): 1879–86.
24. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369–79.
25. Wurzner G, Gerster JC., Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19 (10): 1855–60.
26 Shahinfar S, Simpson RL, Carides AD Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999; 56(5):1879-85.
27 Saruta T, Ogihara T, Matsuoka H Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res. 2007 Aug;0(8):729-39.

Г.А.Барышникова

Кафедра семейной медицины ФГУ "Учебно-научный медицинский центр", Москва

________________________________________________

G.A.Baryshnikova